1 / 8

TRUMA 2008

Pregunta 2. ¿Puede la enfermedad tromboembólica venosa modificar la supervivencia de los pacientes con neoplasias hematológicas? ¿Existe un beneficio, en términos de supervivencia, del tratamiento antitrombótico en pacientes con neoplasias hematológicas?. TRUMA 2008.

carlow
Download Presentation

TRUMA 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pregunta 2 ¿Puede la enfermedad tromboembólica venosa modificar la supervivencia de los pacientes con neoplasias hematológicas? ¿Existe un beneficio, en términos de supervivencia, del tratamiento antitrombótico en pacientes con neoplasias hematológicas? TRUMA 2008

  2. Incidencia de ETEV según el tipo de cancer 4.5 4 3.5 3 2.5 Incidencia de TEV (%) 2 1.5 1 0.5 SNC Útero Recto SMP Colon Riñon Mama Ovario Cervix Hígado Vejiga Esófago Pulmón Próstata Páncreas Estómago Leucemia Linfomas Stein PD et al. Am J Med 2006;119:60-68

  3. TEV y supervivencia en Linfomas • Large B-cell lymphoma (DLBCL) • VTE occurred in 27 of 211 patients (12.8%). • Stage I disease was associated with a low risk, whereas a high • international prognostic index score increased risk • Thrombosis was occurred during the first three cycles in 82%. • The median survival of patients with VTE was 1.04 years (95% CI = 0.75 – 1.33) • compared to 5.2 years (95% CI 1.8 – 8.6) for those without VTE (P = 0.038). Komrojki RS et al. Leukemia & Lymphoma 2006;47:1029-1033

  4. TEV y supervivencia en GMSI / MM Supervivencia (HR; IC 95%) 5 años 10 años Pacientes con MM y TEV 1.0; 0.3 – 3.5 0.8; 0.4 – 1.6 Pacientes con GMSI y TEV 1.7; 1.3 – 2.2 1.6; 1.3 – 2.0 Sigurdur Y et al. Blood 2010;115:4991-4998

  5. TEV y supervivencia en LMA Ku GH et al. Blood 2009;113:3911-3917

  6. TEV y supervivencia en LLA Ku GH et al. Blood 2009;113:3911-3917

  7. Tratamiento anticoagulante y supervivencia en cáncer Che DH et al. Eur J Intern Med 2013;24:433-449

  8. HBPM muestran propiedades antitumorales en neopasias hematológicas. Estudios in vitro e in vivo • Heparin induces the apoptosis of lymphoblasts by the activation of the • intrinsic pathway1 • Bemiparin and ULMWH RO-14 reduce the endotelial angiogenic features • elicited by leukemia2 • Heparin inhibist P388D1 cells adherence and metastasis to peripheral • lymph nodes3 1 Erduran E et al. J Pediatr Hematol Oncol 2012;34:26-29 2 Vignoli A et al. Cancer Invest 2011; 29:153-161 3 Wei W et al. Lymphology 2009; 42:10-18

More Related